clinical trial · NCT07134088
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic LeukemiaBlinatumomab
brief summary
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
started
Dec 8, 2025
primary completion
Mar 6, 2031
completion
Sep 16, 2032
last updated
Oct 5, 2026
official title
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants With Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol